Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cerebrolysin for recovery after acute ischemic stroke
ISRCTN88122184Phase 4Completed
- Sponsor
- Foundation for the Study of Neuroscience and Neuroregeneration
- Start
- Jun 2020
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Native Peptides → Peptides, Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in ischemic stroke comparing Cerebrolysin with Placebo (2 arms). Primary endpoints: Stroop Color-Word Test at Day 360, Trail Making Test Part A at Day 360 and 4 more. Started Jun 2020; status: completed.
02
Drugs
cerebrolysin
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ISRCTN88122184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN88122184.